Novel epigenetic therapies in hematological malignancies: Current status and beyond (2018)
Attributed to:
Characterising and targeting aberrant enhancer function in acute myeloid leukaemia (AML)
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.17863/cam.12327
Publication URI: https://www.repository.cam.ac.uk/handle/1810/267479
Type: Journal Article/Review